Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines

International Journal of Cancer

Volumn 129, Issue 2, 2011, Pages 497-506

  Liu, Xiao Yun ^a   Pop, Laurentiu M ^a   Tsai, Lydia ^a   Pop, Iliodora V ^a   Vitetta, Ellen S ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

CD19; Hematological malignancies; Monoclonal antibodies; Tetravalent

Indexed keywords

CD19 ANTIBODY; CD19 ANTIGEN; FC RECEPTOR; MONOCLONAL ANTIBODY; ANTIIDIOTYPIC ANTIBODY; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BURKITT LYMPHOMA; CANCER CELL DESTRUCTION; CANCER SURVIVAL; CELL PHAGOCYTOSIS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TRANSPORT; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; IMMUNOLOGY; MOUSE MUTANT; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; ANTINEOPLASTIC AGENTS; BURKITT LYMPHOMA; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, SCID; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79961103819     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25695     Document Type: Article

References (50)

1. Weiner LM, Surana R, Wang S. Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010;10:317-27.
2. Haidar JH, Shamseddine A, Salem Z, Mrad YA, Nasr MR, Zaatari G, Bazarbachi A. Loss of CD20 expression in relapsed lymphomas after rituximab therapy. Eur J Haematol 2003;70:330-2. (Pubitemid 36560534)
3. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999;5:611-15. (Pubitemid 29131971)
4. Kennedy GA, Tey SK, Cobcroft R, Marlton P, Cull G, Grimmett K, Thomson D, Gill, D. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: A retrospective review. Br J Haematol 2002;119:412-16. (Pubitemid 35365492)
5. Tedder TF, Isaacs CM. Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily. J Immunol 1989;143:712-17. (Pubitemid 19191574)
6. Chalupny NJ, Aruffo A, Esselstyn JM, Chan PY, Bajorath J, Blake J, Gilliland LK, Ledbetter JA, Tepper MA. Specific binding of Fyn and phosphatidylinositol 3-kinase to the B cell surface glycoprotein CD19 through their src homology 2 domains. Eur J Immunol 1995;25:2978-84.
7. Tuveson DA, Carter RH, Soltoff SP, Fearon DT. CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. Science 1993; 260:986-9. (Pubitemid 23209973)
8. Uckun FM, Burkhardt AL, Jarvis L, Jun X, Stealey B, Dibirdik I, Myers DE, Tuel-Ahlgren L, Bolen JB. Signal transduction through the CD19 receptor during discrete developmental stages of human B-cell ontogeny. J Biol Chem 1993;268:21172-84. (Pubitemid 23292304)
9. Weng WK, Jarvis L, LeBien TW. Signaling through CD19 activates Vav/mitogenactivated protein kinase pathway and induces formation of a CD19/Vav/ phosphatidylinositol 3-kinase complex in human B cell precursors. J Biol Chem 1994;269:32514-21.
10. Depoil D, Fleire S, Treanor BL, Weber M, Harwood NE, Marchbank KL, Tybulewicz VL, Batista FD. CD19 is essential for B cell activation by promoting B cell receptorantigen microcluster formation in response to membrane-bound ligand. Nat Immunol 2008;9:63-72. (Pubitemid 350286205)
11. Aiba Y, Kameyama M, Yamazaki T, Tedder TF, Kurosaki T. Regulation of B-cell development by BCAP and CD19 through their binding to phosphoinositide 3-kinase. Blood 2008;111: 1497-503. (Pubitemid 351213438)
12. Uckun FM, Jaszcz W, Ambrus JL, Fauci AS, Gajl-Peczalska K, Song CW, Wick MR, Myers DE, Waddick K, Ledbetter, JA. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 1988;71:13-29. (Pubitemid 18050385)
13. Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma 1995;18: 385-97.
14. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 1994;63:1424-33.
15. Yazawa N, Poe JC, Tedder TF. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci USA 2005;102:15178-83. (Pubitemid 41513355)
16. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, et al. Tumor regression in cancer patients by very low doses of a T cellengaging antibody. Science 2008;321:974-7.
17. Vallera DA, Elson M, Brechbiel MW, Dusenbery KE, Burns LJ, Jaszcz WB, Ramsay NK, Panoskaltsis-Mortar A, Kuroki DW, Wagner JE, Vitetta ES, Kersey JH. Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody. Cancer Biother Radiopharm 2004;19:11-23. (Pubitemid 38352281)
18. Zalevsky J, Leung IW, Karki S, Chu SY, Zhukovsky EA, Desjarlais JR, Carmichael DF, Lawrence CE. The impact of Fc engineering on an anti-CD19 antibody: Increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood 2009;113:3735-43.
19. Gerber HP, Kung-Sutherland M, Stone I, Morris-Tilden C, Miyamoto J, McCormick R, Alley SC, Okeley N, Hayes B, Hernandez-Ilizaliturri FJ, McDonagh CF, Carter PJ, et al. Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas. Blood 2009;113:4352-61.
20. Herrera L, Stanciu-Herrera C, Morgan C, Ghetie V, Vitetta, ES. Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia. Leuk Lymphoma 2006;47:2380-7. (Pubitemid 44768433)
21. Chu SY, Vostiar I, Karki S, Moore GL, Lazar GA, Pong E, Joyce PF, Szymkowski DE, Desjarlais JR. Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies. Mol Immunol 2008;45:3926-33.
22. Ghetie MA, Picker LJ, Richardson JA, Tucker K, Uhr JW, Vitetta ES. Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. Blood 1994;83:1329-36.
23. Ghetie MA, Marches R, Kufert S, Vitetta ES. An anti-CD19 antibody inhibits the interaction between P-glycoprotein (P-gp) and CD19, causes P-gp to translocate out of lipid rafts, and chemosensitizes a multidrug-resistant (MDR) lymphoma cell line. Blood 2004;104:178-83. (Pubitemid 38879855)
24. Stone MJ, Sausville EA, Fay JW, Headlee D, Collins RH, Figg WD, Stetler-Stevenson M, Jain V, Jaffe ES, Solomon D, Lush RM, Senderowicz A, et al. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 1996;88:1188-97. (Pubitemid 26276793)
25. Messmann RA, Vitetta ES, Headlee D, Senderowicz AM, Figg WD, Schindler J, Michiel DF, Creekmore S, Steinberg SM, Kohler D, Jaffe ES, Stetler-Stevenson M, et al. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Clin Cancer Res 2000;6: 1302-13. (Pubitemid 30226212)
26. Stanciu-Herrera C, Morgan C, Herrera L. Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in Pre-B acute lymphoblastic leukemia cell lines. Leuk Res 2008;32: 625-32. (Pubitemid 351255553)
27. Vitetta ES, Uhr JW. Monoclonal antibodies as agonists: An expanded role for their use in cancer therapy. Cancer Res 1994;54: 5301-9. (Pubitemid 24336017)
28. Ghetie MA, Podar EM, Ilgen A, Gordon BE, Uhr JW, Vitetta ES. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc Natl Acad Sci USA 1997;94:7509-14. (Pubitemid 27345346)
29. Wolff EA, Schreiber GJ, Cosand WL, Raff HV. Monoclonal antibody homodimers: Enhanced antitumor activity in nude mice. Cancer Res 1993;53:2560-5. (Pubitemid 23168023)
30. Meng R, Smallshaw JE, Pop LM, Yen M, Liu X, Le L, Ghetie MA, Vitetta ES, Ghetie V. The evaluation of recombinant, chimeric, tetravalent antihuman CD22 antibodies. Clin Cancer Res 2004;10: 1274-81. (Pubitemid 38365217)
31. Miller K, Meng G, Liu J, Hurst A, Hsei V, Wong WL, Ekert R, Lawrence D, Sherwood S, DeForge L, Gaudreault J, Keller G, et al. Design, construction, and in vitro analyses of multivalent antibodies. J Immunol 2003;170:4854-61. (Pubitemid 36519997)
32. Liu XY, Pop LM, Roopenian DC, Ghetie V, Vitetta ES, Smallshaw JE. Generation and characterization of a novel tetravalent anti-CD22 antibody with improved antitumor activity and pharmacokinetics. Int Immunopharmacol 2006;6: 791-9.
33. Coloma MJ, Hastings A, Wims LA, Morrison SL. Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J Immunol Methods 1992; 152:89-104.
34. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu RR, Santora L, Davis-Taber R, Kunes Y, et al. Simultaneous targeting of multiple disease mediators by a dual-variabledomain immunoglobulin. Nat Biotechnol 2007;25:1290-7. (Pubitemid 350076510)
35. Coleman EJ, Brooks KJ, Smallshaw JE, Vitetta, ES. The Fc portion of UV3, an anti-CD54 monoclonal antibody, is critical for its antitumor activity in SCID mice with human multiple myeloma or lymphoma cell lines. J Immunother 2006; 29:489-98. (Pubitemid 44395274)
36. Kyriakos RJ, Shih LB, Ong GL, Patel K, Goldenberg DM, Mattes MJ. The fate of antibodies bound to the surface of tumor cells in vitro. Cancer Res 1992;52:835-42.
37. Ong GL, Mattes MJ. Re-evaluation of the concept of functional affinity as applied to bivalent antibody binding to cell surface antigens. Mol Immunol 1993;30:1455-62.
38. Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R, Desjarlais JR, Zhukovsky EA. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 2008;68:8049-57.
39. Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM, Jr, Roda JM, Cheney C, Mo X, Lehman A, Jones J, Flynn J, et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fcdomain-engineered monoclonal antibody. Blood 2010;115:1204-13.
40. Hulett MD, Hogarth PM. Molecular basis of Fc receptor function. Adv Immunol 1994;57:1-123.
41. Nezlin R, Ghetie, V. Interactions of immunoglobulins outside the antigencombining site. Adv Immunol 2004;82: 155-215. (Pubitemid 38209511)
42. Salvesen GS, Dixit VM. Caspases: Intracellular signaling by proteolysis. Cell 1997:91:443-6. (Pubitemid 27508233)
43. Porter AG, Jänicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ 1999;6:99-104. (Pubitemid 29082297)
44. Danial NN, Korsmeyer SJ. Cell death. Cell 2003;116:205-19.
45. Lartigue L, Kushnareva Y, Seong Y, Lin H, Faustin B, Newmeyer DD. Caspaseindependent mitochondrial cell death results from loss of respiration, not cytotoxic protein release. Mol Biol Cell 2009;20:4871-84.
46. Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: Implications for therapeutic antibodies. Int Immunol 2001;13:1551-9. (Pubitemid 33133882)
47. Ghetie V, Ward ES. Transcytosis and catabolism of antibody. Immunol Res 2002; 25:97-113. (Pubitemid 34264097)
48. Martin WL, West AP, Jr, Gan L, Bjorkman PJ. Crystal structure at 2.8 A of an FcRn/ heterodimeric Fc complex: Mechanism of pH-dependent binding. Mol Cell 2001;7: 867-77. (Pubitemid 32436446)
49. Gokbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol 2009;46:64-75.
50. Loisel S, Ohresser M, Pallardy M, Dayde D, Berthou C, Cartron G, Watier H. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Crit Rev Oncol Hematol 2007;62:34-42. (Pubitemid 46330797)